Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 13.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | eport is incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 10.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 14.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | activity. 1 Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
Stammdaten
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Unternehmen & Branche
| Name | BridgeBio Oncology Therapeutics, Inc. |
|---|---|
| Ticker | BBOT |
| CIK | 0001869105 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 654,9 Mio. USD |
| Beta | 0,51 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -134,044,000 | -4.30 | 448,381,000 | 411,096,000 | |
| 2025-09-30 | 10-Q | -44,757,000 | -1.03 | 484,793,000 | 446,700,000 | |
| 2025-06-30 | 10-Q | -28,435,000 | 197,390,337 | -227,733,000 | ||
| 2025-03-31 | 10-Q | -22,055,000 | 195,677,952 | -200,033,000 | ||
| 2024-12-31 | 10-K | -74,275,000 | -###.## | 164,301,000 | -178,637,000 | |
| 2024-09-30 | 10-Q | -17,323,000 | -###.## | 192,332,795 | -159,207,000 | |
| 2024-06-30 | 10-Q | -21,823,000 | 189,874,488 | -143,441,000 | ||
| 2024-03-31 | 10-Q | -15,442,000 | 187,528,744 | -128,866,000 | ||
| 2023-12-31 | 10-K | -41,692 | 332,894 | -115,641,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.